CytomX Therapeutics (CTMX) vs Kamada (KMDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kamada (KMDA) has outperformed CytomX Therapeutics (CTMX) over the past year, gaining 14.7% versus a loss of 47.7%. Over five years, KMDA leads with a +22.7% price change compared with -69.9% for CTMX. Kamada is the larger company by market cap ($446.8 million vs $442.5 million), about 1.0 times the size.
Kamada pays a dividend yielding 7.24%, while CytomX Therapeutics does not currently pay one. Kamada converts more of its revenue into profit, with a net margin of 11.2% versus -22.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTMX | KMDA |
|---|---|---|
| Share price | $2.03 | $7.74 |
| Market cap | $442.55M | $446.85M |
| 1-day change | -0.98% | -1.15% |
| YTD return | -52.35% | +9.63% |
| 1-year return | -47.68% | +14.67% |
| 5-year return | -69.93% | +22.66% |
| P/E ratio (TTM) | — | 20.37 |
| Forward P/E | — | 13.34 |
| EPS (TTM) | $-0.51 | $0.38 |
| Dividend yield | 0.00% | 7.24% |
| Annual dividend | $0.00 | $0.56 |
| Revenue (latest FY) | $76.20M | $180.46M |
| Revenue growth (YoY) | -44.82% | +12.12% |
| Net income (latest FY) | $-17.37M | $20.20M |
| Gross margin | — | 42.34% |
| Operating margin | -29.35% | 14.54% |
| Net margin | -22.79% | 11.19% |
| 52-week high | $8.21 | $9.35 |
| 52-week low | $1.87 | $6.63 |
| Distance from 52-week high | -75.27% | -17.22% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +509.85% | +77.65% |
| Average volume | 4.27M | 121.87K |
| Shares outstanding | 218.00M | 57.73M |
| Employees | 69 | 462 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KMDA has outperformed CTMX by 62.3 percentage points over the past year.
- Kamada offers a meaningfully higher dividend yield (7.24% vs 0.00%).
- Kamada is more profitable, keeping 11.2 cents of every revenue dollar as net income versus -22.8 cents for CytomX Therapeutics.
- Kamada grew revenue faster in its latest fiscal year (+12.12% vs -44.82%).
About CytomX Therapeutics
CTMX stock →CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Kamada
KMDA stock →Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees
CTMX vs KMDA FAQ
Which is bigger, CytomX Therapeutics or Kamada?
Kamada (KMDA) is larger, with a market capitalization of $446.85M compared with $442.55M for CytomX Therapeutics (CTMX).
Which stock has performed better over the past year, CTMX or KMDA?
KMDA returned +14.67% over the past 12 months, compared with -47.68% for CTMX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, CytomX Therapeutics or Kamada?
Kamada pays a dividend yielding 7.24%, while CytomX Therapeutics does not currently pay a regular dividend.
Are CytomX Therapeutics and Kamada in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.